Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

327 ARTÍCULOS , VIENDO DEL 1 AL 15

Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase?

Wirz KT, Keitel S, Swaab DF, Verhaagen J, Bossers K.

J Alzheimers Dis. 2014;38(4):719-40. doi: 10.3233/JAD-130920.

A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease

Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Kaye J.

J Alzheimers Dis. 2014;38(1):111-20. doi: 10.3233/JAD-130722.

The Centers for Medicare & Medicaid Services and amyloid-β positron emission tomography for Alzheimer disease

Steinbrook R.

JAMA Intern Med. 2014 Jan;174(1):135. doi: 10.1001/jamainternmed.2013.11705.

Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions

Pearson SD, Ollendorf DA, Colby JA.

JAMA Intern Med. 2014 Jan;174(1):133-4. doi: 10.1001/jamainternmed.2013.11711.

Stroop effects in Alzheimer's disease: selective attention speed of processing, or color-naming? A meta-analysis

Ben-David BM, Tewari A, Shakuf V, Van Lieshout PH.

J Alzheimers Dis. 2014;38(4):923-38. doi: 10.3233/JAD-131244.

Art therapy for Alzheimer's disease and other dementias

Chancellor B, Duncan A, Chatterjee A.

J Alzheimers Dis. 2014;39(1):1-11. doi: 10.3233/JAD-131295.

Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders

Roussotte FF, Daianu M, Jahanshad N, Leonardo CD, Thompson PM.

Brain Imaging Behav. 2014 Jun;8(2):217-233. doi: 10.1007/s11682-013-9263-y.

The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease

Ohnishi T, Sakiyama Y, Okuri Y, Kimura Y, Sugiyama N, Saito T, Takahashi M, Kobayashi T.

Curr Alzheimer Res. 2014 Feb;11(2):110-8. doi: 10.2174/15672050113106660167.

GSK3 in Alzheimer's disease: mind the isoforms

Ma T.

J Alzheimers Dis. 2014;39(4):707-10. doi: 10.3233/JAD-131661.

Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis

Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, Kofler JK, Klunk WE, Lopez OL, Sweet RA.

J Alzheimers Dis. 2014;39(4):759-73. doi: 10.3233/JAD-131166.

Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction

Ungar L, Altmann A, Greicius MD.

Brain Imaging Behav. 2014 Jun;8(2):262-73. doi: 10.1007/s11682-013-9272-x.

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2

Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2014 Jan;22(1):14-24. doi: 10.1016/j.jagp.2013.02.014.

Imaging markers of structural and functional brain changes that precede cognitive symptoms in risk for Alzheimer's disease

Burggren A, Brown J.

Brain Imaging Behav. 2014 Jun;8(2):251-61. doi: 10.1007/s11682-013-9278-4.

Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: a systematic review and meta-analysis

Zhang J, Zhang CH, Li RJ, Lin XL, Chen YD, Gao HQ, Shi SL.

J Alzheimers Dis. 2014;40(1):153-9. doi: 10.3233/JAD-131445.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias